Detalles de la búsqueda
1.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439329
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38818978
3.
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.
Eur J Haematol
; 111(6): 922-929, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37747757
4.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
5.
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Am J Hematol
; 92(3): 244-250, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28006855
6.
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Chemotherapy
; 62(6): 353-356, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28810255
7.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107338
8.
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.
Blood
; 128(16): 2093-2095, 2016 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27549308
9.
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.
Am J Hematol
; 93(2): E35-E37, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29098721
10.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Front Oncol
; 11: 624405, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33763359
11.
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
J Clin Med
; 8(6)2019 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31248142
12.
Venetoclax for the treatment of chronic lymphocytic leukemia.
Expert Opin Investig Drugs
; 26(11): 1307-1316, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28972395
13.
Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.
Leuk Res
; 57: 65-71, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28292720
14.
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
Leukemia
; 32(8): 1869-1873, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29588545
15.
Pomalidomide in multiple myeloma.
Expert Opin Pharmacother
; 18(2): 133-137, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28002973
Resultados
1 -
15
de 15
1
Próxima >
>>